CliffBio
biologic

LYFGENIA

lovotibeglogene autotemcel

Loss of exclusivityDecember 2035projected — 12-year biologic exclusivity estimate
CompanyGenetix Biotherapeutics Inc.

Drug detail

Brand nameLYFGENIA
Active ingredientlovotibeglogene autotemcel
Strength1.7-20x10^6CELL/ML
Dosage formSuspension
RouteIntravenous
ModalityBiologic
FDA approvalDecember 2023
Marketing statusRx

More from Genetix Biotherapeutics Inc.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

LYFGENIA patent cliff — loss of exclusivity December 2035 | CliffBio